In delivering care to patients with cancer, the oncology community is dependent on the availability of accurate, evidence-based treatment information, largely gleaned from the outcomes of clinical trials or high-quality observational studies. At a time when clinicians are encouraged to provide more tailored and patient-centered care,1 including the patient’s voice as a component of evidence generation is critical. Patient values and preferences can influence treatment choice. In addition, physician knowledge of comorbid conditions, preexisting patient symptoms, and adverse effects of treatment are essential. During the past 2 decades, we have seen increased incorporation of patient-reported outcomes (PROs) as part of clinical trial assessments to bridge the gap between patient preferences and physician practice, in the form of multidimensional health-related quality of life and symptom assessment.2 Regulatory bodies now endorse inclusion of such measures as part of regulatory approvals of drugs.3 However, delivering high-quality patient-centered care is complex, especially as the health care system undergoes dramatic changes, as noted in the Institute of Medicine’s (IOM) recent report.1 The IOM recommended that additional efforts be made to collect more detailed information on patient experiences with treatments, as well as more comprehensive information about patient characteristics and behaviors. In this issue of JAMA Oncology, the studies by Basch et al4 and Ye et al5 take important first steps in showing us that it is feasible to obtain expanded information about patient experiences, comorbid conditions, and toxic effects that occur among patients with cancer.4,5
Qureshi ZP, Ganz PA, Bennett CL. Improving the Evidence Base for Delivery of High-Quality Cancer Care. JAMA Oncol. 2017;3(8):1029–1031. doi:10.1001/jamaoncol.2016.6722
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: